A whole-genome SNP association study of NCI60 cell line panel indicates a role of Ca2+ signaling in selenium resistance

PLoS ONE

Volumn 5, Issue 9, 2010, Pages 1-8

  Savas, Sevtap ^a,b   Briollais, Laurent ^a   Ibrahim Zada, Irada ^a,b   Jarjanazi, Hamdi ^a,b   Choi, Yun Hee ^a   Musquera, Mireia ^c   Fleshner, Neil ^d   Venkateswaran, Vasundara ^c   Ozcelik, Hilmi ^a,b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^d PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ION; CYCLIC AMP DEPENDENT PROTEIN KINASE ANCHORING PROTEIN; CYCLIC AMP DEPENDENT PROTEIN KINASE ANCHORING PROTEIN 6; CYCLIC GMP DEPENDENT PROTEIN KINASE; DELTA SARCOGLYCAN; DNA; LARGE CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL; SELENIUM; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; CALCIUM;

APOPTOSIS; ARTICLE; CALCIUM SIGNALING; CANCER CELL CULTURE; CELL STRAIN LNCAP; CHEMOPROPHYLAXIS; CHROMOSOME 10Q; CHROMOSOME 14Q; CHROMOSOME 5Q; CONTROLLED STUDY; DIET SUPPLEMENTATION; DNA DETERMINATION; DRUG RESISTANCE; EPISTASIS; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC MODEL; HUMAN; HUMAN CELL; INTRON; PROTEIN INTERACTION; SINGLE NUCLEOTIDE POLYMORPHISM; DRUG EFFECT; GENETICS; MALE; METABOLISM; PATHOPHYSIOLOGY; PROSTATE TUMOR; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

APOPTOSIS; CALCIUM; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; SELENIUM; SIGNAL TRANSDUCTION;

EID: 77958617652     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0012601     Document Type: Article

References (60)

1. Letavayova L, Vlckova V, Brozmanova J (2006) Selenium: from cancer prevention to DNA damage. Toxicology 227: 1-14.
2. Diwadkar-Navsariwala V, Diamond AM (2004) The link between selenium and chemoprevention: a case for selenoproteins. J Nutr 134: 2899-2902.
3. Platz EA, Helzlsouer KJ (2001) Selenium, zinc, and prostate cancer. Epidemiol Rev 23: 93-101.
4. Meuillet E, Stratton S, Prasad Cherukuri D, Goulet AC, Kagey J, et al. (2004) Chemoprevention of prostate cancer with selenium: an update on current clinical trials and preclinical findings. J Cell Biochem 91: 443-458.
5. Neill MG, Fleshner NE (2006) An update on chemoprevention strategies in prostate cancer for 2006. Curr Opin Urol 16: 132-137.
6. Efferth T, Volm M (2005) Pharmacogenetics for individualized cancer chemotherapy. Pharmacol Ther 107: 155-176.
7. Shastry BS (2002) SNP alleles in human disease and evolution. J Hum Genet 47: 561-566.
8. Koo SH, Lee EJ (2006) Pharmacogenetics approach to therapeutics. Clin Exp Pharmacol Physiol 33: 525-532.
9. Kerb R (2006) Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett 234: 4-33.
10. Shoemaker RH (2006) The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 6: 813-823.
11. Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, et al. (2001) DbSNP: the NCBI database of genetic variation. Nucleic Acids Res 29: 308-311.
12. Venkateswaran V, Klotz LH, Fleshner NE (2002) Selenium modulation of cell proliferation and cell cycle biomarkers in human prostate carcinoma cell lines. Cancer Res 62: 2540-2545.
13. Papp LV, Holmgren A, Khanna KK (2009) Selenium and selenoproteins in health and disease. Antioxid Redox Signal.
14. Vinceti M, Maraldi T, Bergomi M, Malagoli C (2009) Risk of chronic low-dose selenium overexposure in humans: insights from epidemiology and biochemistry. Rev Environ Health 24: 231-248.
15. Jackson MI, Combs GF, Jr. (2008) Selenium and anticarcinogenesis: underlying mechanisms. Curr Opin Clin Nutr Metab Care 11: 718-726.
16. Lippman SM, Goodman PJ, Klein EA, Parnes HL, Thompson IM, Jr., et al. (2005) Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst 97: 94-102.
17. Brinkman M, Reulen RC, Kellen E, Buntinx F, Zeegers MP (2006) Are men with low selenium levels at increased risk of prostate cancer? Eur J Cancer 42: 2463-2471.
18. Combs GF, Jr. (2004) Status of selenium in prostate cancer prevention. Br J Cancer 91: 195-199.
19. Duffield-Lillico AJ, Dalkin BL, Reid ME, Turnbull BW, Slate EH, et al. (2003) Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU Int 91: 608-612.
20. Micke O, Schomburg L, Buentzel J, Kisters K, Muecke R (2009) Selenium in oncology: from chemistry to clinics. Molecules 14: 3975-3988.
21. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, et al. (2009) Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 301: 39-51.
22. Sanmartin C, Plano D, Palop JA (2008) Selenium compounds and apoptotic modulation: a new perspective in cancer therapy. Mini. Rev. Med. Chem 8: 1020-1031.
23. Zeng H, Combs GF, Jr. (2007) Selenium as an anticancer nutrient: roles in cell proliferation and tumor cell invasion. J Nutr Biochem.
24. Whanger PD (2004) Selenium and its relationship to cancer: an update dagger. Br J Nutr 91: 11-28.
25. Nadiminty N, Gao AC (2008) Mechanisms of selenium chemoprevention and therapy in prostate cancer. Mol Nutr Food Res 52: 1247-1260.
26. Uguz AC, Naziroglu M, Espino J, Bejarano I, Gonzalez D, et al. (2009) Selenium Modulates Oxidative Stress-Induced Cell Apoptosis in Human Myeloid HL-60 Cells Through Regulation of Calcium Release and Caspase-3 and -9 Activities. J Membr Biol.
27. Selenius M, Rundlof AK, Olm E, Fernandes AP, Bjornstedt M (2009) Selenium and selenoproteins in the treatment and diagnostics of cancer. Antioxid Redox Signal.
28. Zheng Y, Zhong L, Shen X (2005) Effect of selenium-supplement on the calcium signaling in human endothelial cells. J Cell Physiol 205: 97-106.
29. Chigbrow M, Nelson M (2001) Inhibition of mitotic cyclin B and cdc2 kinase activity by selenomethionine in synchronized colon cancer cells. Anticancer Drugs 12: 43-50.
30. Menter DG, Sabichi AL, Lippman SM (2000) Selenium effects on prostate cell growth. Cancer Epidemiol Biomarkers Prev 9: 1171-1182.
31. Jarjanazi H, Kiefer J, Savas S, Briollais L, Tuzmen S, et al. (2008) Discovery of genetic profiles impacting response to chemotherapy: application to gemcitabine. Hum Mutat 29: 461-467.
32. Calderone V (2002) Large-conductance, ca(2+)-activated k(+) channels: function, pharmacology and drugs. Curr Med Chem 9: 1385-1395.
33. Amberg GC, Bonev AD, Rossow CF, Nelson MT, Santana LF (2003) Modulation of the molecular composition of large conductance, Ca(2+) activated K(+) channels in vascular smooth muscle during hypertension. J Clin Invest 112: 717-724.
34. Burgoyne JR, Madhani M, Cuello F, Charles RL, Brennan JP, et al. (2007) Cysteine redox sensor in PKGIa enables oxidant-induced activation. Science 317: 1393-1397.
35. Moss SB, Gerton GL (2001) A-kinase anchor proteins in endocrine systems and reproduction. Trends Endocrinol Metab 12: 434-440.
36. McCartney S, Little BM, Langeberg LK, Scott JD (1995) Cloning and characterization of A-kinase anchor protein 100 (AKAP100). A protein that targets A-kinase to the sarcoplasmic reticulum. J Biol Chem 270: 9327-9333.
37. Grunnet M, Kaufmann WA (2004) Coassembly of Big Conductance Ca2+- activated K+ Channels and L-type Voltage-gated Ca2+ Channels in Rat Brain. J Biol Chem 279: 36445-36453.
38. Ghatta S, Nimmagadda D, Xu X, O'Rourke ST (2006) Large-conductance, calcium-activated potassium channels: structural and functional implications. Pharmacol Ther 110: 103-116.
39. Alioua A, Tanaka Y, Wallner M, Hofmann F, Ruth P, et al. (1998) The large conductance, voltage-dependent, and calcium-sensitive K+ channel, Hslo, is a target of cGMP-dependent protein kinase phosphorylation in vivo. J Biol Chem 273: 32950-32956.
40. Fukao M, Mason HS, Kenyon JL, Horowitz B, Keef KD (2001) Regulation of BK(Ca) channels expressed in human embryonic kidney 293 cells by epoxyeicosatrienoic acid. Mol Pharmacol 59: 16-23.
41. Lohmann SM, Vaandrager AB, Smolenski A, Walter U, De Jonge HR (1997) Distinct and specific functions of cGMP-dependent protein kinases. Trends Biochem Sci 22: 307-312.
42. Ruth P (1999) Cyclic GMP-dependent protein kinases: understanding in vivo functions by gene targeting. Pharmacol Ther 82: 355-372.
43. Hofmann F (2005) The biology of cyclic GMP-dependent protein kinases. J Biol Chem 280: 1-4.
44. Roh S, Choi S, Lim I (2007) Involvement of Protein Kinase A in Nitric Oxide Stimulating Effect on a BK(Ca) Channel of Human Dermal Fibroblasts. J Invest Dermatol.
45. Tian L, Coghill LS, McClafferty H, MacDonald SH, Antoni FA, et al. (2004) Distinct stoichiometry of BKCa channel tetramer phosphorylation specifies channel activation and inhibition by cAMP-dependent protein kinase. Proc Natl Acad Sci U S A 101: 11897-11902.
46. Dodge-Kafka KL, Kapiloff MS (2006) The mAKAP signaling complex: integration of cAMP, calcium, and MAP kinase signaling pathways. Eur J Cell Biol 85: 593-602.
47. Wheeler MT, McNally EM (2003) Sarcoglycans in vascular smooth and striated muscle. Trends Cardiovasc Med 13: 238-243.
48. Ueyama T, Ohkusa T, Hisamatsu Y, Nakamura Y, Yamamoto T, et al. (1998) Alterations in cardiac SR Ca(2+)-release channels during development of heart failure in cardiomyopathic hamsters. Am J Physiol 274: H1-7.
49. Lipskaia L, Pinet C, Fromes Y, Hatem S, Cantaloube I, et al. (2007) Mutation of delta-sarcoglycan is associated with Ca(2+) -dependent vascular remodeling in the Syrian hamster. Am J Pathol 171: 162-171.
50. Khaitan D, Sankpal UT, Weksler B, Meister EA, Romero IA, et al. (2009) Role of KCNMA1 gene in breast cancer invasion and metastasis to brain. BMC Cancer 9: 258.
51. Bloch M, Ousingsawat J, Simon R, Schraml P, Gasser TC, et al. (2007) KCNMA1 gene amplification promotes tumor cell proliferation in human prostate cancer. Oncogene 26: 2525-2534.
52. Noguchi S, Aihara T, Koyama H, Motomura K, Inaji H, et al. (1994) Discrimination between multicentric and multifocal carcinomas of the breast through clonal analysis. Cancer 74: 872-877.
53. Ochiai T, Ueda K, Urata Y, Yamano T, Konishi E, et al. (1996) [Clonal analysis of hepatocellular carcinoma]. Gan To Kagaku Ryoho 23 Suppl 2: 182-188.
54. Wang S, Su Q, Zhu S, Liu J, Hu L, et al. (2002) Clonality of multiple uterine leiomyomas. Zhonghua Bing Li Xue Za Zhi 31: 107-111.
55. Ozawa E, Mizuno Y, Hagiwara Y, Sasaoka T, Yoshida M (2005) Molecular and cell biology of the sarcoglycan complex. Muscle Nerve 32: 563-576.
56. Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, et al. (2005) Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436: 117-122.
57. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, et al. (2007) PLINK: A Tool Set for Whole-Genome Association and Population-Based Linkage Analyses. Am J Hum Genet 81: 559-575.
58. Hochberg Y, Benjamini Y (1990) More powerful procedures for multiple significance testing. Stat Med 9: 811-818.
59. Frazer KA, Ballinger DG, Cox DR, Hinds DA, Stuve LL, et al. (2007) A second generation human haplotype map of over 3.1 million SNPs. Nature 449: 851-861.
60. Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21: 263-265.